{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:54:26Z","timestamp":1789707266621,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.vaccine.2017.04.080","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T19:07:59Z","timestamp":1494356879000},"page":"3342-3346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain"],"prefix":"10.1016","volume":"35","author":[{"given":"Esther","family":"Navarro-Illana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"L\u00f3pez-Lacort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Navarro-Illana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Vilata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Diez-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.04.080_b0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2334-13-39","article-title":"Systematic review of the incidence and prevalence of genital warts","volume":"13","author":"Patel","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.080_b0010","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1086\/514722","article-title":"Genital warts and their treatment","volume":"28","author":"Beutner","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.080_b0015","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/OLQ.0b013e3181632d61","article-title":"Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999\u20132004","volume":"35","author":"Dinh","year":"2008","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2017.04.080_b0020","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1086\/522863","article-title":"The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries","volume":"196","author":"Kjaer","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.080_b0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-2458-10-113","article-title":"The quality of life of patients with genital warts: a qualitative study","volume":"10","author":"Mortensen","year":"2010","journal-title":"BMC Pub Health"},{"key":"10.1016\/j.vaccine.2017.04.080_b0030","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1186\/1471-2458-13-1065","article-title":"Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK","volume":"13","author":"Dominiak-Felden","year":"2013","journal-title":"BMC Pub Health"},{"key":"10.1016\/j.vaccine.2017.04.080_b0035","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1111\/j.1468-3083.2012.04493.x","article-title":"2012 European guideline for the management of anogenital warts","volume":"27","author":"Lacey","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.vaccine.2017.04.080_b0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12325-015-0178-4","article-title":"Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review","volume":"32","author":"Mariani","year":"2015","journal-title":"Adv Ther"},{"issue":"Suppl 8","key":"10.1016\/j.vaccine.2017.04.080_b0045","doi-asserted-by":"crossref","first-page":"I1","DOI":"10.1016\/j.vaccine.2013.07.026","article-title":"Comprehensive control of human papillomavirus infections and related diseases","volume":"31","author":"Bosch","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.080_b0050","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.eimc.2015.03.018","article-title":"Human papillomavirus vaccine. Efficacy and safety","volume":"33","author":"Bruni","year":"2015","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.vaccine.2017.04.080_b0055","unstructured":"Kjaer S, Nyg\u00e5rd M, Dillner J, Marshall B, Hansen B, Sigurdardottir L, et al. Long-term effectiveness and safety of GardasilTM in the Nordic countries abstract. EUROGIN 2015 Int Multidiscip Congr HPV Infect Relat Cancers Transl Res Innov into Improv Pract Febr 4\u20137; 2015, Sevilla, Spain. OC 6\u20131."},{"key":"10.1016\/j.vaccine.2017.04.080_b0060","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.04.080_b0065","doi-asserted-by":"crossref","first-page":"e0132404","DOI":"10.1371\/journal.pone.0132404","article-title":"Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: a cohort study","volume":"10","author":"Dominiak-Felden","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.080_b0070","doi-asserted-by":"crossref","first-page":"f2032","DOI":"10.1136\/bmj.f2032","article-title":"Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data","volume":"346","author":"Ali","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2017.04.080_b0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/infdis\/jiu370","article-title":"Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data","volume":"211","author":"Smith","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.080_b0080","first-page":"51","article-title":"Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services","volume":"124","author":"Oliphant","year":"2011","journal-title":"N Z Med J"},{"key":"10.1016\/j.vaccine.2017.04.080_b0085","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/cid\/civ364","article-title":"Dose-related differences in effectiveness of human papillomavirus vaccination against genital warts: a nationwide study of 550,000 young girls","volume":"61","author":"Blomberg","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.080_b0090","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/jnci\/djt032","article-title":"Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study","volume":"105","author":"Leval","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2017.04.080_b0095","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/OLQ.0b013e3182756efd","article-title":"Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany \u2013 an ecologic study","volume":"40","author":"Mikolajczyk","year":"2013","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2017.04.080_b0100","doi-asserted-by":"crossref","first-page":"e1131","DOI":"10.1542\/peds.2014-2961","article-title":"The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts","volume":"135","author":"Smith","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.04.080_b0105","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.2105\/AJPH.2012.301182","article-title":"Prevalence of anogenital warts among participants in private health plans in the United States, 2003\u20132010: potential impact of human papillomavirus vaccination","volume":"103","author":"Flagg","year":"2013","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2017.04.080_b0110","unstructured":"Nsouli-Maktabi H, Ludwig SL, Yerubandi UD, Gaydos JC. Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine. MSMR 2013;20:17\u201320."},{"key":"10.1016\/j.vaccine.2017.04.080_b0115","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of ten years of real-world experience","volume":"63","author":"Garland","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.080_b0120","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.080_b0125","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/infdis\/jit361","article-title":"Declining genital warts in young women in England associated with HPV 16\/18 vaccination: an ecological study","volume":"208","author":"Howell-Jones","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.080_b0130","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1186\/1471-2334-13-463","article-title":"Herpes zoster surveillance using electronic databases in the Valencian Community (Spain)","volume":"13","author":"Morant-Talamante","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.080_b0135","series-title":"Vaccination information system (SIV)","author":"Pastor-Villalba","year":"2009"},{"key":"10.1016\/j.vaccine.2017.04.080_b0140","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12879-015-0811-5","article-title":"Effectiveness of rotavirus vaccines, licensed but not funded, against rotavirus hospitalizations in the Valencia Region, Spain","volume":"15","author":"P\u00e9rez-Vilar","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.080_b0145","unstructured":"International Epidemiological Association. Good Epidemiological Practice (GEP). IEA guidelines for proper conduct in epidemiological research; November 2007 n.d. <http:\/\/ieaweb.org\/good-epidemiological-practice-gep\/> [accessed March 21, 2017]."},{"key":"10.1016\/j.vaccine.2017.04.080_b0150","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1080\/21645515.2015.1049787","article-title":"Intussusception following rotavirus vaccination in the Valencia Region, Spain","volume":"11","author":"P\u00e9rez-Vilar","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.04.080_b0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinthera.2013.12.005","article-title":"The Australian experience with the human papillomavirus vaccine","volume":"36","author":"Garland","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.vaccine.2017.04.080_b0160","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/sextrans-2014-051813","article-title":"Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme","volume":"91","author":"Chow","year":"2015","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2017.04.080_b0165","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.04.080_b0170","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2017.04.080_b0175","first-page":"465","article-title":"WHO position paper, October 2014","volume":"43","author":"Human papillomavirus vaccines","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2017.04.080_b0180","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/infdis\/jit360","article-title":"Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation","volume":"208","author":"Szarewski","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.080_b0185","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/eurpub\/ckn127","article-title":"Epidemiology and cost of treatment of genital warts in Spain","volume":"19","author":"Castellsagu\u00e9","year":"2009","journal-title":"Eur J Pub Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T01:53:59Z","timestamp":1535853239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17305819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":37,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0264410X17305819"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.080","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}